65,437 trials
Crohn's Disease
Primary: Number of Participants With Serious Infections — 132; 47; 18 Participants
Circadian Rhythm Sleep Disorders
Primary: Circadian Phase Shift — -0.48; 0.18; -1.14; -0.50 Hours
Type 1 Diabetes
Primary: Changes in Glycemic Control Measured by A1c — -0.4; 0.0 Changes in A1c in percentage points
Dementia · Memory Disorders
Primary: Performance Characteristics — 86; 79 Percentage of participants
Type 1 Diabetes Mellitus
Primary: Percent Time of Active CTR — 98 percentage of time of active CTR
Fuchs' Dystrophy · Bullous Keratopathy
Primary: Number of Eyes With Immunologic Graft Rejection Episodes — 2; 0 eyes — p=0.17
Diabetes Mellitus
Primary: Weight Change — -3.8; -1.4 kg — p=<.05
Postpartum Contraception
Primary: Breastfeeding — 10; 9 participants
Infections, Papillomavirus
Primary: Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs) — 11; 1; 0; 1 Subjects
Type 1 Diabetes
Primary: Occurrence of Hypoglycemic Episodes — 5; 23 Hypoglycemic Episodes
Prostate Cancer
Primary: Time to Progression — 7.0 months
Diabetes Mellitus, Type 1
Primary: Desire to Receive Advice From Personal Glucose Advisory System (PGASystem) — 100; 92.9; 94.6; 85.7 percentage of participants
Prostate Cancer
Primary: Time to Progression (TTP) — 2.5 months
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…